Shi, Y., Li, J., Xu, J., Sun, Y., Wang, L., Cheng, Y., . . . Ouyang, X. (2019). CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: Promising findings from a prospective, open-label, randomized, phase III trial. Cancer Commun (Lond).
Style de citation ChicagoShi, Yuankai, et al. "CMAB009 Plus Irinotecan Versus Irinotecan-only As Second-line Treatment After Fluoropyrimidine and Oxaliplatin Failure in KRAS Wild-type Metastatic Colorectal Cancer Patients: Promising Findings From a Prospective, Open-label, Randomized, Phase III Trial." Cancer Commun (Lond) 2019.
Style de citation MLAShi, Yuankai, et al. "CMAB009 Plus Irinotecan Versus Irinotecan-only As Second-line Treatment After Fluoropyrimidine and Oxaliplatin Failure in KRAS Wild-type Metastatic Colorectal Cancer Patients: Promising Findings From a Prospective, Open-label, Randomized, Phase III Trial." Cancer Commun (Lond) 2019.